173 related articles for article (PubMed ID: 17698116)
1. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Shariat SF; Park S; Trinh QD; Roehrborn CG; Slawin KM; Karakiewicz PI
J Urol; 2007 Oct; 178(4 Pt 1):1229-36; discussion 1236-7. PubMed ID: 17698116
[TBL] [Abstract][Full Text] [Related]
2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
4. [Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy].
Graefen M; Augustin H; Karakiewicz PI; Hammerer PG; Haese A; Palisaar J; Fernandez S; Noldus J; Erbersdobler A; Cagiannos I; Scardino PT; Kattan MW; Huland H
Urologe A; 2003 May; 42(5):685-92. PubMed ID: 12750804
[TBL] [Abstract][Full Text] [Related]
5. Vascular invasion predicts recurrence after radical prostatectomy: stratification of risk based on pathologic variables.
Ferrari MK; McNeal JE; Malhotra SM; Brooks JD
Urology; 2004 Oct; 64(4):749-53. PubMed ID: 15491714
[TBL] [Abstract][Full Text] [Related]
6. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
[TBL] [Abstract][Full Text] [Related]
7. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
[TBL] [Abstract][Full Text] [Related]
8. Do younger men have better biochemical outcomes after radical prostatectomy?
Freedland SJ; Presti JC; Kane CJ; Aronson WJ; Terris MK; Dorey F; Amling CL;
Urology; 2004 Mar; 63(3):518-22. PubMed ID: 15028449
[TBL] [Abstract][Full Text] [Related]
9. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
10. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
12. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
13. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
14. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
[TBL] [Abstract][Full Text] [Related]
16. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
[TBL] [Abstract][Full Text] [Related]
17. Independent prognostic importance of microvessel density in clinically localized prostate cancer.
Halvorsen OJ; Haukaas S; Høisaeter PA; Akslen LA
Anticancer Res; 2000; 20(5C):3791-9. PubMed ID: 11268456
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
Inman BA; Harel F; Audet JF; Meyer F; Douville P; Fradet Y; Lacombe L
Eur Urol; 2005 May; 47(5):695-702. PubMed ID: 15826765
[TBL] [Abstract][Full Text] [Related]
19. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy.
Chun FK; Briganti A; Lebeau T; Fradet V; Steuber T; Walz J; Schlomm T; Eichelberg C; Haese A; Erbersdobler A; McCormack M; Perrotte P; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2006 Feb; 49(2):273-8; discussion 278-9. PubMed ID: 16413103
[TBL] [Abstract][Full Text] [Related]
20. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
